AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference
16 févr. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819
28 janv. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
26 janv. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
21 janv. 2021 08h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma CEO Issues Letter to Shareholders
08 janv. 2021 09h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference
07 janv. 2021 08h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted,...
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
30 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
17 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and statistical analysis to remain the same DELRAY BEACH, Fla., Nov. 17, 2020 (GLOBE...
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
10 nov. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
AzurRx BioPharma Announces Formation of Scientific Advisory Board
21 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Globally recognized experts in cystic fibrosis and chronic pancreatitis care and research to support AzurRx in advancing the clinical development of MS1819 NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE)...